<DOC>
	<DOCNO>NCT01810588</DOCNO>
	<brief_summary>In trial , aim improve outcome haplo cord transplant . Haplo cord transplant novel promise way improve transplant outcome . We hypothesize identification graft least 5/6 match inherited paternal antigen ( IPA ) target ( i.e. , cord blood graft share one IPA antigens prospective recipient ) important outcome haplo cord transplant nucleate cell dose . The identification graft large proportion subject may necessitate accept low umbilical cord graft dose . In addition umbilical cord blood transplant , recipient receive stem cell family member ( haplo-identical donor ) . After collection prior infusion , cell purify use device call CliniMACS CD34 selection device . The subject undergo chemotherapy condition regimen prior transplantation . No experimental drug use study , combination drug use condition regimen combination use past .</brief_summary>
	<brief_title>Targeting IPA Matching Non-Inherited Maternal Antigenfor Haplo-Cord Transplantation</brief_title>
	<detailed_description>This clinical trial subject hematologic malignancy ( acute leukemia , myeloproliferative disorder , lymphoma , myeloma ) need donor stem cell transplant , umbilical cord blood transplant think best option . As donor allogeneic transplant , typically try use related family member , brother sister , volunteer donor 'HLA match ' , i.e . share similar protein cell . This study subject match sibling donor match unrelated donor available . For subject commonly use transplant procedure use stem cell one two umbilical cord ( UCB ) newborn . These umbilical cord blood graft , despite completely match recipient , cause problem graft vs host disease ( common complication transplant ) . But tend grow slowly subject often prolong hospital stay high risk complication due low blood count . Umbilical cord blood transplant standard arm protocol . This study use new method bone marrow transplantation call combine haplo-identical cord ( haplo-cord ) transplantation . In procedure , cell relate donor share half HLA protein ( haplo-identical ) collect blood , well cell umbilical cord , transplant . It hop use cell haplo-identical relative , subject faster recovery require few transfusion . Over time haplo-identical cell relative replace cell cord blood . The combined transplantation haplo-identical stem cell cord blood previously use approximately 60 subject encouraging result . Traditionally felt important determinant outcome UCB stem cell transplant cord blood cell dose . The second determinant degree match donor recipient . Many time , difficulty identify UCB unit sufficient cell dose well match . Of interest , prior study haplo-cord SCT indicate outcome seem independent UCB cell dose . If preliminary observation correct , may able improve outcome haplo cord transplant accept low threshold UCB dose rather focus optimal matching ( include match HLA another characteristic call IPA ) . This primary objective study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Subject must confirm diagnosis : 1 . Previously Relapsed refractory acute leukemia ( myeloid lymphoid ) 2 . Acute leukemia first remission highrisk recurrence 3 . Chronic myelogenous leukemia chronic , accelerate phase blastcrisis 4 . Recurrent refractory malignant lymphoma Hodgkin lymphoma 5 . Chronic lymphocytic leukemia , relapse poor prognostic feature 6 . Multiple myeloma 7 . Myelodysplastic syndrome 8 . Chronic myeloproliferative disease 9 . Hemoglobinopathies 10 . Aplastic anemia Age â‰¥ 18 year Likely benefit allogeneic transplant opinion transplant physician An HLAidentical relate unrelated donor identify within appropriate time frame . Karnofsky ( KPS ) Performance status &gt; 80 Acceptable organ function define : Serum bilirubin : &lt; 2.0mg/dL ALT ( SGPT ) : &lt; 3 X upper limit normal Creatinine Clearance : &gt; 50 mL/min/1.73m2 ( estimate modify MDRD equation ) Ability understand willingness sign write informed consent document Life expectancy severely limited concomitant illness uncontrolled infection Severely decrease Left Ventricular Ejection Fraction ( LVEF ) impair pulmonary function test ( PFT 's ) Evidence chronic active hepatitis cirrhosis HIVpositive Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogeneic transplant</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Acute Leukemia</keyword>
	<keyword>Myeloproliferative disorder</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
</DOC>